Hungary’s Decade of Data Reveals the Harsh Reality of Extensive-Stage Small Cell Lung Cancer

Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, and Hungary has historically carried one of the heaviest lung cancer burdens in Europe. Within this landscape, small cell lung cancer accounts for roughly 15 to 20 percent of all lung cancer cases and is defined by rapid progression, early metastasis, and a strong association with smoking. About two thirds of these tumors are already extensive-stage disease at diagnosis, meaning the cancer has spread beyond the chest and cannot be treated with curative surgery or radiotherapy. For more than two decades, the standard of care for these patients has been first-line etoposide-platinum chemotherapy, a regimen that induces high initial response rates but delivers only a modest survival benefit, with median overall survival typically ranging between 8 and 10 months. Now, a comprehensive nationwide analysis from Hungary has documented, in unprecedented detail, what this treatment reality looks like across an entire decade.

The study, published in Pathology and Oncology Research, drew on the National Health Insurance Fund, a claims database that covers nearly the entire Hungarian population and records diagnoses, reimbursed prescriptions, medical interventions, and demographic data. Researchers led by Krisztina Bogos of the National Korányi Institute of Pulmonology in Budapest identified 8,104 patients with extensive-stage small cell lung cancer who received first-line etoposide-platinum chemotherapy between 2013 and 2022. To isolate true extensive-stage disease, the team excluded patients who had received concomitant chemoradiotherapy or curative thoracic surgery, treatment patterns characteristic of limited-stage disease, and consulted available histology results to confirm lung cancer pathology. The resulting cohort is one of the largest national datasets of its kind in Central Europe and provides a national benchmark for outcomes in the era before immunotherapy became widely available in Hungary.

The epidemiological findings reveal shifting demographics that mirror broader smoking trends across Central and Eastern Europe. Nearly half of all patients, 47.9 percent, were aged 60 to 69 years at diagnosis, but the age distribution gradually moved toward older groups over the decade. In 2013, 22 percent of patients were aged 70 or above; by 2022, that proportion had risen to 35.1 percent, while the share of patients under 50 declined from 5.14 percent to 3.75 percent. The gender gap also narrowed steadily. Men accounted for 53.1 percent of cases overall, but the male-to-female ratio evened out from 53.7 versus 46.3 percent in 2013 to an exact 50 versus 50 percent split by 2022, a pattern consistent with the Korányi Bulletin’s documentation of the total lung cancer population shifting from 84 percent male in 1980 to 53 percent male in 2022.

Regional analysis uncovered striking geographic variation in incidence. Using 2022 county population data from the Hungarian Central Statistical Office as a reference, Baranya County recorded the highest incidence at 136.4 cases per 100,000 people, well above the national average of 82.7 per 100,000. The authors note that Baranya’s mining history, including the operation of a uranium mine between 1957 and 1997, may hypothetically have contributed to this pattern through historical environmental exposures, and several studies have reported associations between air pollution and small cell lung cancer risk. However, they caution that these interpretations remain speculative and that no causal relationship can be established from the present data.

Treatment patterns documented a clear shift in chemotherapy practice. Carboplatin-based regimens dominated throughout the study period, accounting for 71 percent of cases overall, and the carboplatin-to-cisplatin ratio moved from 63 versus 37 percent in 2013 to 87 versus 13 percent in 2022, reflecting the gradual replacement of cisplatin with the generally better-tolerated carboplatin. Treatment intensity varied considerably: 46 percent of patients completed two to four cycles of etoposide-platinum, 34 percent underwent five or more cycles, and 20 percent received only a single cycle, a halt in treatment that likely reflects chemotherapy intolerance or rapid clinical deterioration. Radiotherapy was frequent, with 38.4 percent of the cohort undergoing it at some point, most commonly as a short course of one to two cycles, while only 4.7 percent received long-course thoracic radiotherapy, which generally signals curative-intent sequential chemoradiotherapy associated with limited-stage disease.

Subsequent therapy was common among progressing patients. Overall, 38.7 percent of the full cohort received second-line treatment, and among those patients, etoposide-platinum rechallenge was the most widespread approach, used in 49.7 percent of subsequent-therapy cases. For platinum-refractory patients, cyclophosphamide-epirubicin-vincristine combinations with or without etoposide accounted for 28.1 percent, followed by topotecan at 17.9 percent, other platinum-based doublets at 1.6 percent, and other agents at 2.7 percent. Approximately 6 percent of patients underwent more than two lines of treatment. These patterns align with standard European practices, in which etoposide-platinum rechallenge is preferred for platinum-sensitive relapsed cases, and with the 2013 ESMO guideline recommending intravenous topotecan and the classical CAV regimen for platinum-refractory patients.

For the efficacy analysis, the researchers narrowed the cohort to 5,576 patients who initiated etoposide-platinum within one year of their first lung cancer diagnosis between 2013 and 2019, enabling at least three years of follow-up. Because the insurance database does not record tumor progression directly, progression-free survival was inferred using time to first subsequent therapy or death as a proxy, a method that may slightly prolong the apparent progression-free interval since a patient’s condition can worsen before a new treatment begins. The results were sobering: median progression-free survival was 6.5 months, with only 52.9 percent of patients remaining progression-free at six months, 19 percent at one year, and 5.2 percent at three years. Median overall survival was 9.3 months, with 69.8 percent of patients surviving the first six months, 37.5 percent at one year, 14.9 percent at two years, and 9.2 percent at three years. Of the 5,576 patients, 94.8 percent either received first subsequent therapy or died within the follow-up period, underscoring how relentlessly this disease progresses despite initial treatment.

A sensitivity analysis excluding the 303 patients who received long-course radiotherapy, designed to reduce potential bias from multimodal therapy and to indirectly exclude curative-intent sequential chemoradiotherapy, confirmed the robustness of the primary findings. In that reduced cohort of 5,273 patients, median progression-free survival was 6.3 months with a six-month rate of 51.8 percent and a three-year rate of 5.0 percent, while median overall survival was 8.9 months with a one-year rate of 35.6 percent and a three-year rate of 8.7 percent. The authors note that the slightly longer progression-free survival observed in their study compared with clinical trials can be attributed to the proxy method, since even short delays between radiologic progression and the initiation of subsequent therapy may extend the measured interval. The shorter overall survival, by contrast, likely reflects that real-world patients do not fit the strict eligibility criteria of phase III trials, which typically require performance status 0 to 1, adequate kidney and liver function, and a life expectancy of at least 12 weeks.

These Hungarian outcomes sit squarely within the range of international real-world evidence. France reported an overall survival of 11.8 months and progression-free survival of 6.1 months in its ESME cohort, while Spain reported overall survival of 8.2 months and progression-free survival of 5 months. The findings also align closely with the chemotherapy control arms of the landmark immunotherapy trials: in CASPIAN, which tested durvalumab added to etoposide-platinum, the control arm had a median progression-free survival of 5.4 months with 12- and 24-month rates of 5.3 and 2.9 percent, and in IMpower133, which tested atezolizumab, the control arm had a median progression-free survival of 4.3 months with a six-month rate of 22.4 percent. The consistency between the Hungarian national data and these trial control arms validates the methodology and confirms that the Hungarian extensive-stage small cell lung cancer population behaves as clinical expectations predict.

The study arrives at a pivotal moment. Immunotherapy combinations with etoposide-platinum were accessible in Hungary only through individual requests from 2022 and became nationally reimbursed in 2024, meaning the accumulation of real-world follow-up data on chemo-immunotherapy will take time. Until then, this analysis stands as a reliable national baseline, complementing international evidence as one of the largest extensive-stage small cell lung cancer cohorts in Europe, against which the impact of chemo-immunotherapy in routine practice can be measured. The authors emphasize that the aggressive nature of the disease and the limited efficacy of chemotherapy-based treatments underscore the need to improve existing first-line and subsequent-line options and to introduce novel therapies. They also call for future studies with extended follow-up that incorporate staging, radiotherapy intent, comorbidities, and progression data, and for an ideal cancer registry with standardized coding practices and structured oncologic variables, so that the next decade of Hungarian data can tell a very different story.

Subject of Research: Health

Article Title: Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022)

Article References: Bogos, K., Bajcsay, A., Gálffy, G., Tamási, L., Pápai-Székely, Z., Sárosi, V., Maráz, A., Pálföldi, R., Horváth, L., Hoffer, J., Szécsényi, S., Kirschner, K., Blasszauer, C., Reibl, D., Komka, I., Ascsillán, A. A., Kemény, L. V., & Ostoros, G. (2026). Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022). Pathology & Oncology Research, 32, Article 1612491. https://doi.org/10.3389/pore.2026.1612491

Image Credits: AI Generated

DOI: 10.3389/pore.2026.1612491

Keywords: lung cancer, oncology, small cell lung cancer, real-world evidence, survival outcomes, Hungary, chemotherapy, immunotherapy, Extensive-stage, small, cell, lung